TrianglePUBLICATIONS · 23235801
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2013 Apr
- First author
- Ketterer N
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Ketterer N
- type
- Author
- name
- Coiffier B
- type
- Author
- name
- Thieblemont C
- type
- Author
- name
- Fermé C
- type
- Author
- name
- Brière J
- type
- Author
- name
- Casasnovas O
- type
- Author
- name
- Bologna S
- type
- Author
- name
- Christian B
- type
- Author
- name
- Connerotte T
- type
- Author
- name
- Récher C
- type
- Author
- name
- Bordessoule D
- type
- Author
- name
- Fruchart C
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Ketterer N
- type
- Author
- name
- Coiffier B
- type
- Author
- name
- Thieblemont C
- type
- Author
- name
- Fermé C
- type
- Author
- name
- Brière J
- type
- Author
- name
- Casasnovas O
- type
- Author
- name
- Bologna S
- type
- Author
- name
- Christian B
- type
- Author
- name
- Connerotte T
- type
- Author
- name
- Récher C
- type
- Author
- name
- Bordessoule D
- type
- Author
- name
- Fruchart C
- type
- Author
- bibliography ids
- nci-bib-52289c4c20cfa2bca014cd7a
- book metadata
- content sha256
- 0b65fff324af9fda999c70c37924b9d867d72266c6c3d0a718722ee11236564c
- document type
- citation
- dois
- 10.1093/annonc/mds600
- electronic publication date
- display
- 2012 Dec 12
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:23235801
- immutable id
- pubmed:23235801@0b65fff324af9fda999c70c37924b9d867d72266c6c3d0a718722ee11236564c
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 4
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 1032-7
- volume
- 24
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 23235801
- provenance
- batch id
- 99e85dbb34a1a3011c9a
- provider
- NCBI PubMed ESummary
- record sha256
- 4c0c6ec8d204df31662b1698f2bd50d0e15adb95667e67e7193735882ab3538b
- response sha256
- 1f4a46dcee9da36f8f58fe356dce3f44a1b3004f404e9fb0184f4e08aed4acf2
- retrieved at
- 2026-09-09T23:46:52.860383+00:00
- publication date
- display
- 2013 Apr
- precision
- month
- year
- 2013
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Preserved source evidence · Independent clinical review pending · Not medical advice